Arjo is a global supplier of medical devices, services, and solutions that improve quality of life for people with reduced mobility and age-related health challenges. We create value by improving clinical outcomes for patients and enabling a better work environment for healthcare professionals. We thereby contribute to a sustainable healthcare system – always with people in mind.
Our main customers are private and public institutions within acute care and long-term care. Our offering includes products and solutions for patient handling, hygiene, disinfection, medical beds, therapeutic surfaces, venous thromboembolism (VTE) prevention, and diagnostics. We also offer services such as training in connection with product sales.
We operate in more than 60 countries, which has been divided into three geographic areas: North America, Western Europe, and Rest of the World. We have more than 5900 employees worldwide. Our head office is in Malmö, Sweden.
BBI LLC (Bruin Biometrics) is a pioneer in sensor based medical devices and is committed to the development of assessment devices for early identification and monitoring of chronic, preventable conditions. Our mission is to modernize care pathways through developing and collaboratively integrating new-to-the-world biometric-sensor based medical devices. The company's lead product is the SEM Scanner, a hand-held wireless device that identifies increased risk of pressure ulcers 5 days earlier (median)1 than current standard of care.
The SEM Scanner is commercially available in the USA and Canada and is also available in a number of European countries as well as Australia, New Zealand.
1. Okonkwo H. et al NPUAP 2018
MIMEDX is an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental biologics, we have both a base business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments.
Next Science® is a medical technology company headquartered in Sydney, Australia, with a research and development center based in Jacksonville, Florida. Established in 2012, the company’s primary focus is on the development and continued commercialization of its proprietary XBIO Technology to reduce the impact of biofilm-based infections in human health.